We are updating our Privacy Policy and Terms and Conditions to help you clearly understand how your personal information is collected, stored and managed. Learn More
Menu Back toStatistical-Challenges-in-Assessing-Drugs-Efficacy-by-Utilizing-Biomarker-Endpoints

DIA 2018 Global Annual Meeting

The DIA 2018 Global Annual Meeting brings together thousands of innovators from around the globe.

Statistical Challenges in Assessing Drugs’ Efficacy by Utilizing Biomarker Endpoints

    Session Chair(s)
      Min  Min, PhD

      Min Min, PhD

      • Mathematical Statistician, OB, OTS, CDER
      • FDA, United States
    This session will provide a platform for researchers to discuss the challenges and issues they faced, share the lessons they learned, and offer possible strategies for future development programs in assessing drug's efficacy by utilizing biomarkers.
    Learning Objective : Discuss the issues and challenges facing future development programs in assessing drug's efficacy by utilizing biomarker endpoints and develop possible strategies.
      Haoda  Fu

      Individualized Treatment Recommendation Through Machine Learning Algorithms

      Haoda Fu

      • Senior Research Scientist
      • Eli Lilly and Company, United States
      Bettina  Hansen

      Validation of Biomarkers as a Surrogate for Clinical Endpoints: The Global PBC Experience

      Bettina Hansen

      • Associate Professor, Senior Biostatistician
      • Institute of Health Policy, Management and Evaluation (IHPME), Univ of Toronto, Canada
      Aloka  Chakravarty, PhD

      Assessment of Concordance Between BNiomarkers and Clinical Outcomes Response to Drug Interventions

      Aloka Chakravarty, PhD

      • Acting Director, Office of Biostatistics, Office of Translational Sciences, CDER
      • FDA, United States